BTAI today
$0.07-$0.04 (-37.11%)close Sep 4, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minNo data
Daily trend turns down below $0.75
Key levels
Resistance$0.92
Resistance$0.80
Latest news & SEC filings
NewsBioXcel Therapeutics reports leadership shifts and plans to wind down
SEC FilingBioXcel Therapeutics, Inc. filed a report on a major company event (Form 8-K)
DealTeva closes deal to buy BioXcel Therapeutics brain-drug holdings
All BTAI news →OTC · Healthcare
BioXcel Therapeutics, Inc. (BTAI)
What Is the Price Target for BTAI?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is BTAI a Buy or Sell Right Now?
Thesis
- •Revenue growing -71.7% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BTAI.
Start Free Trial →Is BTAI Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
PEG
Fair Value
$0.07
29
Moat Score
NONE
2/9
Piotroski Score
-26.4
Altman Z-Score
What Is Smart Money Doing with BTAI?
Insider Signal
SELLING
0 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Yocca Frank | officer | Sale | 6,845 | $7K | May 20, 2026 |
| Rodriguez Javier | officer | Sale | 6,560 | $7K | May 20, 2026 |
| Steinhart Richard I | officer | Sale | 6,845 | $7K | May 20, 2026 |
| Mehta Vimal | director officer | Sale | 19,419 | $21K | May 20, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BTAI Growth Story
Revenue YoY
-71.7%
3yr Revenue CAGR
N/A%
EPS Growth YoY
75.63%
FCF Growth YoY
20.0%
Revenue Trend
DECLINING
Dark Pool Trades for BTAI
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BTAI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 23:59:30 | $0.04 | 1,895 | $$80 | SELL |
| 23:59:14 | $0.04 | 3,900 | $$164 | SELL |
| 23:59:10 | $0.04 | 4,037 | $$170 | SELL |
| 23:58:49 | $0.04 | 1,500 | $$63 | SELL |
| 23:58:19 | $0.04 | 68,502 | $$3K | SELL |
5 dark pool trades shown · $$3K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for BioXcel Therapeutics, Inc. (BTAI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BTAI — frequently asked questions
What is BTAI stock price today?
BioXcel Therapeutics, Inc. (BTAI) is at $0.07, down 37.11% (-$0.04) at the Sep 4, 2026 close.
Why is BTAI stock moving today?
Latest BTAI news — Nov 1, 2026: BioXcel Therapeutics reports leadership shifts and plans to wind down · Oct 30, 2026: BioXcel Therapeutics, Inc. filed a report on a major company event (Form 8-K)
What do analysts rate BTAI?
Analyst ratings for BTAI: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did BTAI beat earnings?
BTAI last reported on Aug 13, 2026: EPS -$0.49 vs -$0.44 expected — a miss of 11.4%.
Does BTAI pay a dividend?
BTAI does not currently pay a dividend.
How much debt does BTAI have?
BioXcel Therapeutics, Inc. reported $104M of debt and $13M of cash (Jun 30, 2026).
What are BTAI support and resistance levels?
Resistance: $0.80, $0.92, $1.05.
What are insiders doing with BTAI?
Insider activity: SELLING, 0 buys and 4 sells in the last 90 days.
What is the latest news on BTAI?
Nov 1, 2026: BioXcel Therapeutics reports leadership shifts and plans to wind down · Oct 30, 2026: BioXcel Therapeutics, Inc. filed a report on a major company event (Form 8-K) · Oct 28, 2026: Teva closes deal to buy BioXcel Therapeutics brain-drug holdings